Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873741 · ClinicalTrials.gov registry record
New Strategies to Assess Anal Cancer Risk In Women
A clinical trial of Human Immunodeficiency Virus (HIV) and Human Papillomavirus (HPV), sponsored by Emory University.
- Completed
- Registry status
- 143
- Enrollment target
- 1
- Study location
NCT02873741 is a study of Human Immunodeficiency Virus (HIV) and Human Papillomavirus (HPV) that has completed, run by Emory University. The registered enrollment target is 143 participants, below the 501-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02873741, a study of Human Immunodeficiency Virus (HIV) and Human Papillomavirus (HPV), has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 143 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study different strategies to identify women at highest risk for anal cancer. Primarily, investigators want to study a risk assessment called the Anal Cancer Risk Index; it gives women an overall number score based on risk factors that they may have for anal cancer, such as age, number of sexual partners, or smoking. Investigators seek to understand whether women with higher Anal Cancer Risk Index scores are more likely to have abnormal results on anal pap smears, HPV tests, or anal biopsies. The study team will collect swabs of the cervix and the anus to study different laboratory tests that could identify women at highest risk of cervical and anal cancer. These laboratory tests include an anal pap smear, tests for markers of disease and tests that detect the HPV types most likely to cause cancer. The study team would like to see which of these laboratory tests do the best job at predicting precancerous lesions in the anus and are better indicators of risk for cancer. After collecting these swabs, women will have a procedure called high resolution anoscopy where investigators look closely at the anus and biopsy any suspicious areas. Finally, the study team will look for HPV proteins and changes that HPV can make in cells to see if these tests predict anal lesions.
Conditions Studied
Interventions
- PROCEDURE Perianal and Digital Anorectal Exam
- PROCEDURE Cervical Swabs
- PROCEDURE Anal Swabs
- PROCEDURE High Resolution Anoscopy (HRA)
Study Locations (1)
Georgia
- The Ponce Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873741
The ClinicalTrials.gov registry entry for NCT02873741 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (71% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Immunodeficiency Virus (HIV) appearing as the primary indexed condition, and to 4 interventions - of which Perianal and Digital Anorectal Exam is the first listed.
NCT02873741 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02873741 about?
NCT02873741 is a clinical study titled "New Strategies to Assess Anal Cancer Risk In Women". The purpose of this research is to study different strategies to identify women at highest risk for anal cancer. Primarily, investigators want to study a risk assessment called the Anal Cancer Risk Index; it gives women an overall number score based on risk factors that they may have for anal cancer...
What is the current status of trial NCT02873741?
This trial is currently completed. The enrollment target is 143 participants. The study started on 2016-07. Estimated completion is 2017-02-27.
What conditions does trial NCT02873741 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV).
What interventions are being tested in trial NCT02873741?
The interventions under investigation include: Perianal and Digital Anorectal Exam (PROCEDURE), Cervical Swabs (PROCEDURE), Anal Swabs (PROCEDURE), High Resolution Anoscopy (HRA) (PROCEDURE).
Who is sponsoring clinical trial NCT02873741?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02873741 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus (HIV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Persuasive Health Communication Intervention for HIV/HCV
RECRUITING · NA
-
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
RECRUITING · NA
-
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
RECRUITING · Phase 3
-
The Trans-Led Care Study
RECRUITING · NA
-
Project neuroARTEMIS
RECRUITING · NA
-
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.